Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is …

Dec 26, 2024 · Johnson & Johnson is expected to post earnings of $2 per share for the current quarter, representing a year-over-year change of -12.7%. Over the last 30 days, the Zacks …

CouponFollow Extension

7%
OFF

Johnson & Johnson (JNJ) Is Attracting Investor Attention: Here Is …

3 weeks from now

Dec 26, 2024 · Johnson & Johnson is expected to post earnings of $2 per share for the current quarter, representing a year-over-year change of -12.7%. Over the last 30 days, the Zacks …

yahoo.com

3%
OFF

Johnson & Johnson (JNJ) Is Attracting Investor Attention: Here Is …

3 weeks from now

Nov 19, 2024 · Johnson & Johnson reported revenues of $22.47 billion in the last reported quarter, representing a year-over-year change of +5.3%. EPS of $2.42 for the same period …

zacks.com

3%
OFF

Johnson & Johnson (JNJ) Is Attracting Investor Attention: Here

3 weeks from now

Nov 19, 2024 · Johnson & Johnson reported revenues of $22.47 billion in the last reported quarter, representing a year-over-year change of +5.3%. EPS of $2.42 for the same period …

nasdaq.com

9%
OFF

Johnson & Johnson Stock Skids After Dow Giant Beat Earnings …

3 weeks from now

Jan 22, 2025 · But Johnson & Johnson stock tumbled 1.9%, closing at 145.27. Shares are now well below their 50-day moving average , according to MarketSurge . J&J Earnings Beat, …

investors.com

41%
OFF

Johnson & Johnson: A Potential Beneficiary Of A Great Rotation

3 weeks from now

JNJ's 3.41% dividend yield and attractive forward PE ratio of 13.5 offer potential upside if value stocks regain market attention. While speculative, buying JNJ now at a good valuation with a …

seekingalpha.com

4%
OFF

Johnson & Johnson Makes $15 Billion Bet On Mental-health Drugs

3 weeks from now

Jan 13, 2025 · Johnson & Johnson's (JNJ) stock rose 0.4%. Johnson & Johnson said it would pay $132 a share for Intra-Cellular. The stock closed at $94.87 a share on Friday. ... Here’s what …

morningstar.com

FAQs about Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is … Coupon?

Is Johnson & Johnson (JNJ) a good stock to buy?

Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Johnson & Johnson is rated Zacks Rank #3 (Hold). Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store. ...

Is Johnson & Johnson a good stock for income-oriented investors?

In this article, you will learn five reasons why I believe Johnson & Johnson is an appealing stock for income-oriented investors. Johnson & Johnson (NYSE: JNJ) is a major player in the pharmaceutical industry, with a rich portfolio of medications widely used to treat various types of cancer, as well as autoimmune and neurological disorders. ...

Should investors consider JNJ (JNJ)?

Investors should take the time to consider JNJ for their portfolios due to its solid Zacks Ranks, notable earnings and valuation metrics, and impressive Value and VGM Style Scores. Want the latest recommendations from Zacks Investment Research? ...

Does Johnson & Johnson have potential revenue growth?

So, it's important to know a company's potential revenue growth. In the case of Johnson & Johnson, the consensus sales estimate of $22.37 billion for the current quarter points to a year-over-year change of -12.4%. ...

How much Will Johnson & Johnson (J&J) earn per share?

Johnson & Johnson is expected to post earnings of $2 per share for the current quarter, representing a year-over-year change of -12.7%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.3%. The consensus earnings estimate of $9.94 for the current fiscal year indicates a year-over-year change of +0.2%. ...

Does Johnson & Johnson have a tighter business focus?

In my view, what's greatly helping Johnson & Johnson of late is a tighter business focus. For decades, it was a unique but somewhat clunky combination of classic pharmaceutical company and consumer healthcare products purveyor. That ended when it hived off the latter business as the separately managed and traded Kenvue in mid-2023. ...